Sanofi hits Lilly with more Lantus infringement charges

Lantus--Courtesy of Sanofi

Sanofi ($SNY) has already slapped Eli Lilly ($LLY) with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until at least mid-2016. But now, it's filed another, wider suit, this time claiming Lilly's med infringes 7 patents related to the insulin and the devices used to deliver it, Reuters reports. The drug is the French company's top seller, generating nearly $7.8 billion last year. Report | More

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.